RRD 251

12/01/2010 - "In a SK-MEL-28 xenograft experiment, RRD-251 exerted a significant suppression of tumor growth compared with vehicle (P = 0.003). "
07/01/2008 - "This review will highlight the importance of the Rb-Raf-1 interaction in cancer, the search for small molecules capable of disrupting the interaction as well as properties of Rb-Raf-1 disruptors, focusing specifically on RRD-251 (Rb-Raf-1 Disruptor 251). "
12/01/2013 - "RRD-251 significantly reduced tumor growth in vivo accompanied by reduced Rb phosphorylation and lymph node and liver metastasis (P < 0.01). "
12/01/2013 - "Combination of RRD-251 with gemcitabine showed cooperative effect on tumor growth (P < 0.01). "
12/01/2013 - "Inactivation of Rb is thought to be initiated by association with Raf-1 (C-Raf) kinase, and here we determined how RRD-251, a disruptor of the Rb-Raf-1 interaction, affects pancreatic tumor progression. "

02/09/2018 - "The c-Raf modulator RRD-251 enhances nuclear c-Raf/GSK-3/VDR axis signaling and augments 1,25-dihydroxyvitamin D3-induced differentiation of HL-60 myeloblastic leukemia cells."
01/01/2016 - "RRD-251 enhances all-trans retinoic acid (RA)-induced differentiation of HL-60 myeloblastic leukemia cells."

02/03/2012 - "Therefore, agents such as RRD-251 that can target activity of E2F1 may have potential therapeutic benefit against cigarette smoke induced atherosclerosis."

01/01/2016 - "RRD-251 is a small molecule that prevents the interaction of c-Raf and RB, the retinoblastoma tumor suppressor protein. "

12/01/2013 - "To define the antitumor effects of RRD-251 (50 μmol/L), cell-cycle analyses, senescence, cell viability, cell migration, anchorage-independent growth, angiogenic tubule formation and invasion assays were conducted on gemcitabine-sensitive and -resistant pancreatic cancer cells. "